Martin Bergstrand, Ph.D.

Principal Director, MIDD Scientific Lead

Portrait-of-Martin-Bergstrand_Pharmetheus

Bio

  • Co-founded Pharmetheus in 2012, actively working in client projects, serving as MIDD Scientific Lead
  • Expertise includes trial design, pharmacometrics (especially complex pharmacokinetics, mechanism based PKPD and Markov models), and model informed drug development in therapeutic areas such as infectious, metabolic, and cardiovascular diseases
  • Previously worked as part-time Researcher at Uppsala University, Sweden, where he performed pharmacometric research primarily by supervision of Ph.D. students, as Visiting Scientist at Mahidol-Oxford Tropical Medicine Research Unit, Thailand, and Clinical Pharmacology Scientist at AstraZeneca R&D Mölndal, Sweden
  • M.Sc. in Biomedicine (2003) from University of Kalmar, Sweden, and Ph.D. in Pharmaceutical Biosciences (2011) from Uppsala University, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Model-based Analysis with Mechanistic Insights to CAR-T Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene AutoleucelThe visual predictive check and real-world dataReference-corrected VPCs: addressing model evaluation challenges with real-world data and adaptive designsModel-informed pediatric drug development for clevidipineVisual predictive checks for real-world data using propensity-score-matchingA mechanism-based parsimonious CAR-T cell population PK model and its validation via extension to a population PK-tumor size dynamics model: case study with axicabtagene ciloleucel and brexucabtagene autoleucelApparent time dependence and rethinking random effect under single time-to-event modelsModel-based bioequivalence methods open new doors for genericsExposure-response analysis for time-to-event data in the presence of adaptive dosing: efficient approaches and pitfallsDose Modifications in Exposure-Response Analyses of Oncology Drug Development: Brigimadlin Case StudyThe evolving role of in vitro – in vivo correlation in Model-Informed Drug Development: A multi-stakeholder perspective